Niraparib (MK-4827) tosylate

For research use only. Not for use in humans.

目录号:S7625 别名: Niraparib tosylate, MK 4827 tosylate, ZEJULA 中文名称:尼拉帕尼甲苯磺酸盐

Niraparib (MK-4827) tosylate Chemical Structure

CAS No. 1038915-73-9

Niraparib tosylate (MK-4827, ZEJULA) 是PARP1/PARP2的选择性抑制剂,IC50分别为3.8 nM和2.1 nM。Niraparib可增加PARP-DNA复合体的形成,并导致DNA损伤、凋亡和细胞死亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1449.63 现货
RMB 959.15 现货
RMB 3251.76 现货
RMB 8165.6 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Niraparib (MK-4827) tosylate发表文献18篇:

客户使用该产品的1个实验数据:

  • Berberine activates PARP1 in ovarian cancer cells. PAR synthesis is detected by immunofluorescence staining in A2780 and HO8910 treated with different concentration of berberine alone or in combination with niraparib (10 μM) for 48 h. Top: representative examples of immunofluorescence staining of PAR. Scale bar, 20 μm. Bottom: quantification of PAR level in A2780 and HO8910. Immunofluorescence intensities were quantified by ImageJ. *P<0.05, **P<0.01

    Cell Death & Disease, 2017, 8: e3070. Niraparib (MK-4827) tosylate purchased from Selleck.

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Niraparib tosylate (MK-4827, ZEJULA) 是PARP1/PARP2的选择性抑制剂,IC50分别为3.8 nM和2.1 nM。Niraparib可增加PARP-DNA复合体的形成,并导致DNA损伤、凋亡和细胞死亡。
靶点
PARP2 [3]
(Cell-free assay)
PARP1 [3]
(Cell-free assay)
2.1 nM 3.8 nM
体外研究

微摩尔级浓度的niraparib使来自于肺癌、乳腺癌以及前列腺癌的肿瘤细胞对放射线敏感(不依赖于它们的p53状态),而对来自于正常组织的细胞没有此作用。Niraparib同样还可以使肿瘤细胞对过氧化氢敏感、在DNA复制时,将过氧化氢诱导的单链断裂转变为双链断裂[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa M{nRc2Z2dmO2aX;uJIF{e2G7 MXnJcohq[mm2aX;uJI9nKFCDUmCgbY4hcHmmcn;n[Y4heGW{b4jp[IUucW6mdXPl[EBpfW2jbjDI[WxiKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25iRF7BMYRidWGpZT3pcoR2[2WmIGDBVplt[XSrb36sJGVEPTBiPTCwMlAxPCEQvF2u NHHTNZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi3N|k5OSd-MUm4O|M6QDF:L3G+
MDA-MB-436 MVrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NFnuU403KGSjeYO= MkP1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuPDN4IHPlcIx{KGW6cILld5NqdmdiQmLDRVEhPTN7NjCrJFFIRkFibYX0ZY51KGGodHXyJFYh\GG7czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFPDOVAhRSByLkCxPEDPxE1w NFPy[JM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi3N|k5OSd-MUm4O|M6QDF:L3G+
HeLa M{PkemFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NUjheHF[PyCmYYnz M{DWSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRnJESTFiZHXmbYNq\W62IHj1cYFvKEinTHGgZ4VtdHNiYX\0[ZIhPyCmYYnzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygR2M2OCB;IECuNFM{KM7:TT6= NFjEWYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi3N|k5OSd-MUm4O|M6QDF:L3G+
HeLa M{W2fGZ2dmO2aX;uJIF{e2G7 MXLJcohq[mm2aX;uJI9nKFCDUmCgbY4hcHmmcn;n[Y4heGW{b4jp[IUucW6mdXPl[EBpfW2jbjDI[WxiKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25iRF7BMYRidWGpZT3pcoR2[2WmIGDBVplt[XSrb36sJGVEQTBiPTCwMlA1PSEQvF2u MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh5M{m4NUc,OTl6N{O5PFE9N2F-
Capan1 MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M{X1XVE{KGSjeYO= MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOjcHHuNUBk\WyuczDlfJBz\XO|aX7nJGJTS0F{IE[xO|Rl\WyWIH31eIF1cW:wIHHu[EBtd3O|IH;mJJdqdGRvdInw[UBidGynbHWgZYZ1\XJiMUOg[IF6eyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEOFNUCgQUAxNjB7IN88UU4> M1ewUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEezPVgyLz5zOUi3N|k5OTxxYU6=
HeLa MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mo\SO{Bl[Xm| M13JZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBDWkODMTDh[pRmeiB5IHThfZMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBESzVyIE2gNE45PiEQvF2u MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh5M{m4NUc,OTl6N{O5PFE9N2F-
MDA-MB-436 MVzBcpRqfHWvb4KgZZN{[Xl? M1mwS|UxKG2pL3vn M4juPFM{KGSjeYO= MkWzRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTR|NjDj[YxteyCneIDy[ZN{cW6pIFLSR2EyKDV|OU[gL{AyTz6DIH31eIFvfCC6ZX7v[5Ji\nSnZDDpckBETDFibX;1d4Uh[XO|ZYPz[YQh[XNidIXtc5IhemWpcnXzd4lwdiCjdDC1NEBu\y:tZzygdI8h[mmmIH\vdkA{OyCmYYnz MkDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6N{O5PFEoRjF7OEezPVgyRC:jPh?=
MDA-MB-436 MVjBcpRqfHWvb4KgZZN{[Xl? NVLT[5dJOTByIH3nM4to MXezN{Bl[Xm| NYDzd|ZoSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOkBk\WyuczDlfJBz\XO|aX7nJGJTS0FzIEWzPVYhMyBzR{7BJI12fGGwdDD4[Y5w\3KjZoTl[EBqdiCFREGgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JicnXndoV{e2mxbjDheEAyODBibXevb4ctKHCxIIHkJIZweiB|MzDkZZl{ NYLmSJZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4O|M6QDFpPkG5PFc{QThzPD;hQi=>
Jurkat NV\iVIxiTnWwY4Tpc44h[XO|YYm= M{DLSFk3KGi{cx?= NF;PdlVKdmirYnn0bY9vKG:oIGDBVnAyKGmwIHj1cYFvKEq3cnvheEBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZiY3XscEB3cWGkaXzpeJkh[W[2ZYKgPVYhcHK|IHL5JG1VWyCjc4PhfUBqdiCycnXz[Y5k\SCxZjCxNFAhfU1ib3[geIVud3qxbH;tbYRmNCCHQ{WwJF0hOC5{IN88UU4> NXjLTZM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OVAyQTlpPkKzPFUxOTl7PD;hQi=>
Jurkat M1rncWZ2dmO2aX;uJIF{e2G7 NUPCdFltQTZiaILz MWHJcohq[mm2aX;uJI9nKFCDUmCxJIlvKGi3bXHuJGp2emujdDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiOU[gbJJ{KGK7IF3UV{Bie3OjeTygSWM2OCB;IEOxJO69VS5? NXzROm1FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OVAyQTlpPkKzPFUxOTl7PD;hQi=>
CAPAN-1 MWDGeY5kfGmxbjDhd5NigQ>? M2Xrd2lvcGmkaYTpc44hd2ZiUFHSVEBqdiCEUlPBNk1l\W[rY3nlcpQhcHWvYX6gR2FRSU5vMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGi7ZILv[4VvKHCncn;4bYRmNWmwZIXj[YQhWEGUeXzheIlwdiCkeTDj[YxtNWKjc3XkJIF{e2G7LDDJR|UxKD1iMD6wNFM2KM7:TT6= MmHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
HeLa MX\GeY5kfGmxbjDhd5NigQ>? NUn6c|dnUW6qaXLpeIlwdiCxZjDQRXJRKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCqeXTyc4dmdiCyZYLvfIll\S2rbnT1Z4VlKFCDUonsZZRqd25iYomgZ4VtdC2kYYPl[EBie3OjeTygSWM2OCB;IECuNFA1KM7:TT6= MlfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
A2780 NU\QfVRVTnWwY4Tpc44h[XO|YYm= NVu3fFB2UW6qaXLpeIlwdiCxZjDQRXJRKGmwIHj1cYFvKEF{N{iwJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaInkdo9o\W5icHXyc5hq\GVvaX7keYNm\CCSQWL5cIF1cW:wIHL5JINmdGxvYnHz[YQh[XO|YYmsJGlEPTBiPTCwMlAxPCEQvF2u MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUC5Okc,OjV5NkGwPVY9N2F-
A549 M1XuTWN6fG:2b4jpZ4l1gSCjc4PhfS=> M2rOTVUhfG9iNzDkZZl{ MmLvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJTS0F{IIPoVm5CKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFUhfG9iNzDkZZl{KGK7IFPlcIxVcXSncj3CcJVmKGG|c3H5MEBESzVyIE2gNE4xOTFizszNMi=> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUC5Okc,OjV5NkGwPVY9N2F-
MDA-MB-436 NELCR2dEgXSxdH;4bYNqfHliYYPzZZk> MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO2JINmdGy|IHPhdpJ6cW6pIFLSR2EyKG23dHHueEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckwhS0N3MDC9JFAvODF6IN88UU4> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUC5Okc,OjV5NkGwPVY9N2F-
SUM1315MO2 NH3UZ|ZEgXSxdH;4bYNqfHliYYPzZZk> M{TmWFEzKGSjeYO= NUD1TXBFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1WPMUOxOW1QOiClZXzsd{Bk[XK{eXnu[{BDWkODMTDteZRidnRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhOTJiZHH5d{BjgSCFZXzsWIl1\XJvQnz1[UBie3OjeTygR2M2OCB;IECuNFIh|ryPLh?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUC5Okc,OjV5NkGwPVY9N2F-
DoTc2-4510 NY\KepJlS3m2b4TvfIlkcXS7IHHzd4F6 NGqzcWg2KHSxIEeg[IF6ew>? MmPaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSI9V[zJvNEWxNEBk\WyuczDjZZJzgWmwZzDCVmNCOiCvdYThcpQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgOUB1dyB5IHThfZMh[nliQ3XscHRqfGW{LVLseYUh[XO|YYmsJGNEPTBiPTCwMlAzOyEQvF2u NIDQbW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVA6Pid-MkW3OlExQTZ:L3G+
SUM149PT MUXDfZRwfG:6aXPpeJkh[XO|YYm= MWK1JJRwKDdiZHH5dy=> MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTWW0yPDmSVDDj[YxteyClYYLyfYlv\yCEUlPBNUBufXSjboSgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiNTD0c{A4KGSjeYOgZpkhS2WubGTpeIVzNUKudXWgZZN{[XluIFPDOVAhRSByLkCyOEDPxE1w MmfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
HeLa NGrBfldEgXSxdH;4bYNqfHliYYPzZZk> NXLmfFR1PSC2bzC3JIRigXN? M3eyW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMhfHKjboPm[YN1\WRid3n0bEBDWkODMTDzbHJPSSCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiNTD0c{A4KGSjeYOgZpkhS2WubGTpeIVzNUKudXWgZZN{[XluIFPDOVAhRSByLkCzOEDPxE1w MlnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
HeLa M2PjN2Z2dmO2aX;uJIF{e2G7 NUTkNWI1UW6qaXLpeIlwdiCxZjDQRXJRKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCqeXTyc4dmdiCyZYLvfIll\S2rbnT1Z4VlKFCDUonsZZRqd25iYomgZ4VtdC2kYYPl[EBie3OjeTygTWM6OCB;IECuNFQ3KM7:TT6= NUKxZ3l7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlExQTZpPkK1O|YyODl4PD;hQi=>
CAPAN-1 NVPncFRNTnWwY4Tpc44h[XO|YYm= M3WyVWlvcGmkaYTpc44hd2ZiUFHSVEBqdiCEUlPBNk1l\W[rY3nlcpQhcHWvYX6gR2FRSU5vMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGi7ZILv[4VvKHCncn;4bYRmNWmwZIXj[YQhWEGUeXzheIlwdiCkeTDj[YxtNWKjc3XkJIF{e2G7LDDJR|kxKD1iMD6wOUDPxE1w Mnq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
A2780 MYLGeY5kfGmxbjDhd5NigQ>? NYftdWVJUW6qaXLpeIlwdiCxZjDQRXJRKGmwIHj1cYFvKEF{N{iwJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaInkdo9o\W5icHXyc5hq\GVvaX7keYNm\CCSQWL5cIF1cW:wIHL5JINmdGxvYnHz[YQh[XO|YYmsJGlEQTBiPTCwMlA2OiEQvF2u NWHt[5VlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlExQTZpPkK1O|YyODl4PD;hQi=>
UWB1.289 NUDZcIhRS3m2b4TvfIlkcXS7IHHzd4F6 MYG1JJRwKDdiZHH5dy=> MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVW2IyNjJ6OTDj[YxteyClYYLyfYlv\yCEUlPBNUBufXSjboSgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiNTD0c{A4KGSjeYOgZpkhS2WubGTpeIVzNUKudXWgZZN{[XluIFPDOVAhRSByLkC1OkDPxE1w MkDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
Capan1 M{nS[2N6fG:2b4jpZ4l1gSCjc4PhfS=> M{fEcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKUQ1GyMYRm\mmlaXXueEBpfW2jbjDDZZBidjFiY3XscJMtKEOFNUCgQUAxNjB7IN88UU4> NGTjNIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVA6Pid-MkW3OlExQTZ:L3G+
HeLa M2P6WWN6fG:2b4jpZ4l1gSCjc4PhfS=> MXi1JJRwKDdiZHH5dy=> NXnTdVU5S3m2b4TvfIlkcXS7IHHnZYlve3Rid3ns[EB1gXCnIHj1cYFvKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPSC2bzC3JIRigXNiYomgR4VtdFSrdHXyMWJtfWViYYPzZZktKEOFNUCgQUAxNjh3MjFOwG0v NYrWW3JTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlExQTZpPkK1O|YyODl4PD;hQi=>
UWB1.289 MUHDfZRwfG:6aXPpeJkh[XO|YYm= NVLUUXp3PSC2bzC3JIRigXN? M2j5WmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHVYSjFwMki5JINmdGy|IHX4dJJme3OrbnegRnJESTFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPSC2bzC3JIRigXNiYomgR4VtdFSrdHXyMWJtfWViYYPzZZktKEOFNUCgQUAxNjl5NTFOwG0v M4rmPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xNFk3Lz5{NUe2NVA6PjxxYU6=
A549 MkTwR5l1d3SxeHnjbZR6KGG|c3H5 MXe1JJRwKDdiZHH5dy=> NXvCOGNrS3m2b4TvfIlkcXS7IHHnZYlve3Rid3ns[EB1gXCnIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPSC2bzC3JIRigXNiYomgR4VtdFSrdHXyMWJtfWViYYPzZZktKEOFNUCgQUAyNjd4IN88UU4> NHHKZW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVA6Pid-MkW3OlExQTZ:L3G+
BT20 NIi2SpFEgXSxdH;4bYNqfHliYYPzZZk> NXvnOVlkPSC2bzC3JIRigXN? NUXWUIxSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSlR{MDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA2KHSxIEeg[IF6eyCkeTDD[YxtXGm2ZYKtRox2\SCjc4PhfUwhS0N3MDC9JFIvOiEQvF2u MlPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
MDA-MB-436 MUXBcpRqfHWvb4KgZZN{[Xl? MnTNPFAhdWdxa3e= M1Kzd|EhfG9iMjD3[YVsew>? MXPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuPDN4IHPlcIx{KGijcnLvdolv\yCEUlPBNUBufXSjboSgfIVvd2e{YX\0[YQhcW5iaX3teY5w[2:vcILvcYl{\WRibX;1d4Uh[XO|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiOECgcYcwc2duIIDvJJFlKG[xcjCxJJRwKDJid3Xlb5M> M2jGe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xNFk3Lz5{NUe2NVA6PjxxYU6=
MDA-MB-436 NILSdFhCdnSrdIXtc5Ih[XO|YYm= NWLncGx1QDBibXevb4c> NIGy[281KHenZXvz MXHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuPDN4IHPlcIx{KGijcnLvdolv\yCEUlPBNUBufXSjboSgfIVvd2e{YX\0[YQhcW5iaX3teY5w[2:vcILvcYl{\WRibX;1d4Uh[XO|ZYPz[YQh[XNiY3;tdIxmfGViYX7kJJN2e3SjaX7l[EB1fW2xcjDy[Ydz\XO|aX;uJIF1KDhyIH3nM4toNCCybzDx[EBnd3JiNDD3[YVsew>? NYj6W3hnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlExQTZpPkK1O|YyODl4PD;hQi=>
MDA-MB-436 NX7D[4NQSW62aYT1cY9zKGG|c3H5 M4fmSlUxKG2pL3vn M3vSNGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12M{[gZ4VtdHNiaHHyZo9zcW6pIFLSR2EyKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDpcY12dm:lb33wdo9ucXOnZDDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDC1NEBu\y:tZzygdI8h[WSvaX7pd5RmemWmIHThbYx6 MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUC5Okc,OjV5NkGwPVY9N2F-
MDA-MB-436 M3TBOWFvfGm2dX3vdkBie3OjeR?= M2fkOlgxKG2pL3vn NHrzZ4g{KHenZXvz NFHoN4ZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO2JINmdGy|IHjhdoJwemmwZzDCVmNCOSCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gbY1ufW6xY3;tdJJwdWm|ZXSgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3Jic3jybY5s[WenIHH0JFgxKG2pL3vnMEBxdyCzZDDmc5IhOyC5ZXXrdy=> NY[4NlNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlExQTZpPkK1O|YyODl4PD;hQi=>
Capan1 MkL4R5l1d3SxeHnjbZR6KGG|c3H5 MoLTR5l1d3SxeHnjbZR6KGGpYXnud5QhSlKFQUKt[IVncWOrZX70JIh2dWGwIFPhdIFvOSClZXzsd{whTUN3MDC9JFAvPjVizszNMi=> NFTJOFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
TC32 MV;xTHRUKGG|c3H5 NXfvUGN5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGTDN|Ih[2WubIO= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 Ml6zdWhVWyCjc4PhfS=> MnTGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 MUTxTHRUKGG|c3H5 NHH4[ndyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz M13Je|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 M2i3VJFJXFNiYYPzZZk> Mm\sdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k> M4TrO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 MWfxTHRUKGG|c3H5 NUPOdoNJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MoDtdWhVWyCjc4PhfS=> MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= M{LzV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MUPxTHRUKGG|c3H5 NX;zV5pIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> MoHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 NFGxNWxyUFSVIHHzd4F6 NY[1cYxVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz M1\OOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC M{G4NpFJXFNiYYPzZZk> MW\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{ NGTzb|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 NEPw[25yUFSVIHHzd4F6 MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR|MzKGOnbHzz MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
c-PARP /c-caspase 3 / γ-H2AX; 

PubMed: 29158830     


Western Blot data testing protein expression after treatment with Olaparib, Niraparib, and Talazoparib on Brca1-deficient cell line in W0069 cells.

29158830
Immunofluorescence
Rad51 / Geminin; 

PubMed: 27614696     


Immunofluorescence microscopy of niraparib-treated PDX cells (PH039) and irradiated cells showing RAD51 foci (arrow) within geminin positive cells and lack of RAD51 foci formation in control cells. 

27614696
体内研究 MK-4827可以增强放射线对多种人类肿瘤异种移植的作用,无论是在p53野生型或是p53突变体。MK-4827在给药后1小时降低肿瘤中PAR水平并持续效果24小时[1]。MK-4827体内给药能延长放射线处理后的动物寿命。MK-4827和放射治疗结合,显著提高肿瘤中裂解的caspase-3和γ-H2AX的水平[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[2]
- 合并
  • Cell lines: V-C8细胞
  • Concentrations: 50 nM
  • Incubation Time: 24 h
  • Method: 用PARP抑制剂MK-4827对中国仓鼠细胞V-C8(BRCA2-negative)进行处理,24小时后,洗涤并将细胞孵育在不含此化合物的培养基中5-7天,直到形成克隆。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 雌性裸鼠(Ncr Nu/Nu)
  • Dosages: 25或50 mg/kg
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (198.94 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 492.59
化学式

C19H20N4O.C7H8O3S

CAS号 1038915-73-9
储存条件 粉状
溶于溶剂
别名 Niraparib tosylate, MK 4827 tosylate, ZEJULA

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PARP Signaling Pathway Map

相关PARP产品

Tags: 购买Niraparib (MK-4827) tosylate | Niraparib (MK-4827) tosylate供应商 | 采购Niraparib (MK-4827) tosylate | Niraparib (MK-4827) tosylate价格 | Niraparib (MK-4827) tosylate生产 | 订购Niraparib (MK-4827) tosylate | Niraparib (MK-4827) tosylate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID